P06.09 In vitro assessment of human IL-12Fc function on porcine and canine peripheral blood mononuclear cells

ABSTRACT: Abstract Introduction: Despite state-of-the-art surgical methods combined with radio- and chemotherapy the clinical prognosis of brain cancer patients remains poor. The brain is an immune privileged site and brain cancers are known to form a highly immunosuppressive microenvironment, suggesting that patients could benefit from immunomodulatory drugs. Multiple therapies targeting the immune system are currently under development, including application of a potent activator of immune responses, interleukin (IL)-12. This cytokine stimulates the cytotoxic function of lymphocytes and can trigger rejection of gliomas in preclinical studies. Even though IL-12 has a relatively short half-life, systemic IL-12 can quickly lead to severe adverse reactions. Local application or targeting is therefore

SUBMITTER: Schellhammer L 

PROVIDER: S-EPMC5464105 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature